Citations

Clear

363 citation(s) found for "Gray, RJ".

White matter conduction in the human brain is mostly slow, with rare high velocity connections
Romero-Santiago, Samuel , Yáñez-Ramos, María Guadalupe , Bilderbeek, Jordan , Gregg, Nicholas M. , In, Myung‐Ho , Gray, Erin, Kang, Daehun , Shu, Yunhong , Worrell, Gregory A. , McIntyre, Cameron C. , Miller, Kai J. , Bilderbeek, Jordan A , Hermes, Dora , Yanez-Ramos, Maria Guadalupe , Worrell, Gregory A , Gregg, Nicholas M , Kang, Daehun , In, Myung-Ho , Gray, Erin M. , Hermes, Dora

Mayo Clinic

No container title available | July 31, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.07.28.741279 | PMID 42619995 Get It

Abstract White matter bundles play a crucial role in cognitive functions by rapidly transmitting information between brain regions. Inter-areal conduction guides the integration of information and conduction velocity is a fundamental parameter in theories and models of brain function. However, distributions of conduction velocity remain difficult to characterize in vivo in humans. In this work, we integrated diffusion magnetic resonance imaging (dMRI) tractography with intracranial electrical stimulation during clinical stereo-electroencephalography (sEEG) monitoring in 17 subjects to measure conduction velocity within four major white matter bundles. Our findings reveal that human brain conduction is characterized by high variability both within and between bundles, reflecting a predominance of slow connections alongside rare high-speed connections. Because conduction velocity in myelinated fibers follows an approximately linear relationship with axon diameter, we derive underlying axon diameter distributions and show that these estimates are comparable to previous post-mortem studies. These findings demonstrate a heavily skewed distribution of human neural conduction velocities and show that structural heterogeneity shapes the timing and integration of information in large-scale networks.
Characterizing genetic diversity and population structure of gray fox ( Urocyon cinereoargenteus) in the eastern United States using 2bRAD sequencing data
Koller, Adam L, Maldonado, Jesús E. , Clark, William R. , Beringer, Jeff, Albers, Geriann , Hiller, Tim L. , Reding, Dawn M. , Koller, Adam , Koller, Adam L

Mayo Clinic

Journal of Heredity | July 30, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/jhered/esag060 | PMID 42535684 Get It

Abstract Concerns about declining gray fox (Urocyon cinereoargenteus) populations in the Midwest, United States, prompted a petition to list the prairie gray fox subspecies (Urocyon cinereoargenteus ocythous) under the US Endangered Species Act. Although previous studies identified a deep phylogenetic break between eastern and western lineages of the gray fox at the Great Plains Suture Zone, population structure within the Midwest remains poorly understood, complicating subspecies classification. To address this, we genotyped 339 individuals from the eastern lineage of the gray fox using single nucleotide polymorphisms (SNPs) generated from 2bRAD genomic sequencing to assess genetic diversity and structure. Bayesian clustering and principal component analysis supported three genetic clusters (K = 3), revealing a cryptic break within Missouri that subdivides the morphologically defined range of U. c. ocythous and a secondary break coinciding with the Mississippi River and the currently accepted subspecies boundary. However, low pairwise FST values and admixture indicate weak overall genetic differentiation with ongoing gene flow, whereas declining genetic diversity at northern latitudes is reflective of founder effects from post-glacial population expansion. Consistent with prior mitochondrial DNA (mtDNA) results, nuclear SNP data suggest that U. c. ocythous and Urocyon cinereoargenteus cinereoargenteus are unlikely to represent distinct evolutionary units. However, because 2bRAD detects primarily neutral variation, whole-genome sequencing will be needed to test for adaptive divergence that might persist despite gene flow. Our findings provide an important step toward a comprehensive understanding of population structure and refining subspecies boundaries within the eastern lineage of the gray fox.
The ILLUMINATE natural history study in colony-stimulating factor 1 receptor-related adult-onset leukoencephalopathy with axonal spheroids and pigmented glia
Wade, Charles, Hayer, Stefanie N, Gelfand, Jeffrey M, Köhler, Wolfgang , Bergner, Christa-Caroline, Souza, Paulo Victor Sgobbi de, Finger, Elizabeth , Wolf, Nicole I. , Orthmann-Murphy, Jennifer L, Chmiela, Tomasz, Rajagovindan, Raj, McLaren, Donald G, Gaudreault, Francois, Mirescu, Christian, Raitcheva, Denitza, Meier, Andreas, Gray, David, Chavez, Juan, Kaufmann, Petra, Wszolek, Zbigniew K, Chmiela, Tomasz , Lynch, David S , Schöls, Ludger , Köhler, Wolfgang , Finger, Elizabeth C. , Wolf, Nicole I , Beerepoot, Shanice , Chmiela, Tomasz , Wade, Charles , Hayer, Stefanie N. , Gelfand, Jeffrey M. , Bergner, Caroline, Souza, Paulo Victor Sgobbi de , Orthmann‐Murphy, Jennifer , Rajagovindan, Raj, McLaren, Donald G. , Mirescu, Christian, Raitcheva, Denitza , Meier, Andreas , Kaufmann, Petra, Wszołek, Zbigniew K.

Mayo Clinic

Brain Communications | July 11, 2026 | Volume: 8 | Issue: 4 | Pages: No page available

10.1093/braincomms/fcag271 | PMID 42500553 Get It

Abstract Colony-stimulating factor 1 receptor-related adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (CSF1R-ALSP) is a rare, fatal, autosomal-dominant neurodegenerative disorder caused by pathogenic CSF1R variants and characterized by progressive cognitive, neuropsychiatric, and motor dysfunction, white matter lesions on brain imaging, and white matter demyelination, swollen axons, and pigmented glial cells on pathology. Limited data regarding clinical, biofluid or radiological biomarkers of disease severity are available, and no clinical trial endpoints have yet been validated. The objectives of this first-of-its-kind, prospective, observational natural history study were to characterize the clinical trajectory of CSF1R-ALSP and to identify and evaluate key biomarkers and clinical endpoints indicative of disease severity and progression. ILLUMINATE (NCT05020743) was a multicentre, noninterventional natural history study of adults with CSF1R-ALSP and prodromal carriers of CSF1R variants. Participants were followed for up to 36 months, with clinical assessments, fluid biomarkers and volumetric MRI assessments of brain atrophy collected at screening and every 6 months. This study was terminated early (4 June 2025). The analyses reported here include data collected through 19 February 2025. Of 53 participants, 19 were prodromal and 34 were symptomatic (11 of whom had a history of haematopoietic stem cell transplant and 23 who did not). Mean participant age was 47.8 (standard deviation, 4.5) years, and 36.4% were female. Prodromal participants remained relatively stable over 36 months, with little change in neurological function, neurodegeneration biomarkers or radiological disease burden. Impaired neurological function, MRI characteristics of CSF1R-ALSP, and elevated NfL (neurofilament light chain; neurodegeneration biomarker) and GFAP (glial fibrillary acidic protein; astrogliosis biomarker) levels were more pronounced at baseline and often showed progression over time among symptomatic participants who had not previously received haematopoietic stem cell transplant compared with participants who had previously received haematopoietic stem cell transplant. Significant correlations were observed at baseline and longitudinally between MRI measures of brain atrophy and clinical outcome measures. Based on the fluid biomarkers, MRI measures, and clinical outcome assessments evaluated here, active neurodegeneration, widespread changes visualized on brain MRI, and impaired cognitive and motor function were observed in symptomatic patients with CSF1R-ALSP. The neurological impairment can be assessed using the Montreal Cognitive Assessment and Cortical Basal ganglia Functional Scale. Our data suggest that quantification of brain atrophy using MRI volumetry is a potential biomarker of disease severity and progression in CSF1R-ALSP. It is hoped that this report will contribute to the understanding of disease progression in CSF1R-ALSP and inform future drug development.
Calcium and Other Electrolyte Management in Patients Undergoing Leukocytapheresis Collections: Review and Recommendations From the American Society for Apheresis Clinical Applications Committee
Williams, Lance A. , Gray, Kristin , Jacob, R. , Sanchez, Amber P. , Bailey, Hanna , Revia, Richard, Thibodeaux, Suzanne R. , Liu, Hien , Annen, Kyle , Godbey, Elizabeth A , Jacob, Reuben P , Sanchez, Amber P , Thibodeaux, Suzanne , Liu, Hien , Annen, Kyle , Godbey, Elizabeth A. , Revia, Richard A.

Mayo Clinic

Journal of Clinical Apheresis | July 3, 2026 | Volume: 41 | Issue: 4 | Pages: No page available

10.1002/jca.70151 | PMID 42397022 Get It

ABSTRACT Collection of hematopoietic progenitor cells and mononuclear cells by leukocytapheresis is a critical step of procuring cellular starting materials for future therapeutic use. Leukocytapheresis requires use of anticoagulant to prevent blood clotting in the extracorporeal circuit during collection. A commonly used anticoagulant is Acid Citrate Dextrose Solution A (ACD‐A). ACD‐A primarily prevents blood clotting by reversibly chelating free ionized calcium, which is essential for the clotting cascade. Electrolytes frequently affected by ACD‐A include calcium, magnesium, potassium, phosphate, and bicarbonate. Risks for development of electrolyte derangements include procedure‐related parameters as well as patient comorbidities. Symptoms range from mild paresthesias to life‐threatening cardiac arrhythmias. Recognition of related signs and symptoms is important for prompt intervention with procedure modification and electrolyte replacement to optimize patient safety. This paper will provide an enhanced understanding of the underlying pathophysiology and assist in timely identification and management of electrolyte abnormalities associated with cellular therapy collections.
Disease-modifying treatment preferences and decision-making in a multiple sclerosis randomized and observational clinical trial (DELIVER-MS)
Tallantyre, Emma C , Planchon, Sarah M. , Howard, Harriet, Mays, John, Frowd, Nadia, Cohen, Jeffrey A. , Hersh, Carrie M. , Miller, Deborah , Dever, Meredith , Gray, Emma H., LaRocca, Nicholas G., Bale, Clare , Covey-Crump, Gwen, Alvarez, Enrique, Craner, Matt, Freeman, L, Frost, N, Hobart, JC, Hutton, George J, Hyland, Megan , Kalra, S, Kannan, Meena, Kantarci, OH , Lashley, Daniel, Lily, Oliver, Mahad, D, Nicholas, J, Nicholas, R, Paling, David, Pearson, Owen , Rice, Claire M , Samudralwar, Rohini, Schmalstieg, William F., Singh, M, The, E Zune, Zabeti, Aram , Love, Thomas E, Gunzler, Douglas , Liu, Y, GERRY, STEPHEN, Evangelou, N, Hersh, Carrie M , Miller, D M , Nakamura, Kunio , Goldman, Myla D , Harding, Katharine E , Hobart, Jeremy , Kalra, Seema , Nicholas, Richard , Pearson, Owen R , Rice, Claire M , Weinstock‐Guttman, Bianca , Evangelou, Nikos , Ontaneda, Daniel , Cohen, Jeffrey Allen , Tallantyre, Emma Clare , Coles, Alasdair J. , Covey-Crump, Gwen L , Arun, Tarunya , Brownlee, Wallace J , Craner, Matthew J., Freeman, Leorah A. , Goldman, Myla , Gupta, Rajesh , Hutton, George J., Kantarci, Orhun H. , Mahad, Don , Paling, David , The, Ei Zune , Love, Thomas E.

Mayo Clinic

Multiple Sclerosis Journal | May 31, 2026 | Volume: 32 | Issue: 7 | Pages: 722-736

10.1177/13524585261449988 | PMID 42218617 Get It

Background: There is growing support for high-efficacy disease-modifying therapy (DMT) in multiple sclerosis (MS), but escalation (ESC) approaches remain common. Objective: To describe decision-making in a pragmatic trial of early high-efficacy treatment (EHT) versus ESC. Methods: DELIVER-MS is a multi-center, pragmatic, randomized controlled trial (RCT) with a parallel observational study (OBS), which enrolled treatment-naïve people with RRMS in 31 UK/US sites. Primary outcome was as follows: 36-month brain volume loss according to initial treatment approach (EHT vs. ESC). Stepwise multivariable logistic regression was used to predict participation in RCT versus OBS and choice of EHT versus ESC within the OBS cohort. Results: In total, 816 people with MS were enrolled. Participants declined randomization due to preference for a particular DMT (85%), efficacy concerns (20%), and safety concerns (9%). RCT versus OBS participation was associated with lower relapse rate ( p = 0.043) and greater brain parenchymal fraction ( p = 0.002). Among 374 in the OBS cohort, 125 (33%) chose ESC and 249 (67%) chose EHT. People commencing EHT had higher education attainment ( p < 0.001) and relapse rate ( p = 0.025). Conclusion: Baseline DELIVER-MS data demonstrate that participants with milder disease are more likely to participate in RCT. The choice of EHT versus ESC was associated with demographic factors and disease activity. Clinical trial registration: NCT03535298
Differentiating Upper Trunk Brachial Plexopathies From the Electrodiagnostic “Gray Zone” Extraforaminal Cervical Nerve Root Injuries With Brachial Plexus Ultrasound
Meiling, James B. , Pulos, Nicholas, Spinner, Robert J, Shin, Alexander Y, Meiling, James B , Pulos, Nicholas , Spinner, Robert J. , Shin, Alexander Y.

Mayo Clinic

American Journal of Physical Medicine & Rehabilitation | May 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/phm.0000000000003024 | PMID 42155977 Get It

Patients with traumatic brachial plexus injuries (TBPI) undergo clinical examination and electromyography (EMG) to characterize injury severity and localization. However, precise localization with EMG alone can be difficult when multiple injury sites are possible. Brachial plexus ultrasound (BPUS) allows direct visualization of the brachial plexus, a needed adjunct to EMG to reveal multiple sites of injury in TBPI. We summarize three cases of EMG-confirmed upper trunk TBPI which were clarified using BPUS to additionally involve electrically hidden injuries to the extraforaminal C5 and C6 nerve roots. BPUS demonstrated extensive scarring and focal enlargement of the upper trunk in each patient (all cross-sectional area [CSA] ≥24 mm 2 ). However, all patients also had C5 and C6 extraforaminal nerve root enlargement (all CSA ≥9 mm 2 and 12 mm 2 , respectively), revealing further neural involvement proximal to the upper trunk into the EMG “gray zone”– postganglionic, extraforaminal cervical nerve root injury which is clinically and electrodiagnostically indistinguishable from the plexus but anatomically and radiographically distinguishable on BPUS. Some EMG-identified upper trunk TBPI may have more proximal involvement of the contributing extraforaminal C5-6 nerve roots, an area electrically indistinguishable from an upper trunk TBPI without the assistance of advanced imaging.
Optimizing Radiography Utilization: Multidisciplinary Expert Consensus Recommendations Endorsed by the Society of Academic Bone Radiologists, Society of Skeletal Radiology, American Society of Emergency Radiology,
Rilland, Eddy D. Zandee van , Fayad, Laura M. , Link, Thomas M. , Davis, Kirkland W. , Wu, Jim S. , Chang, Eric Y. , Chow, Lawrence C. , Desai, Shaun C., Fritz, Jan, Gorbachova, Tetyana , Gray, Mingyang L., Gross, Joel A. , Ha, Patrick K., Halle, Tyler R. , Hall, M. Kennedy, Lee, Mark A. , Mann, Edana D. , Obey, Mitchel R. , Osgood, Greg M., Patel, Zara M. , Rendon, Juan M. , Sabbatini, Amber K. , Tannoury, Chadi , Yu, Joseph S. , Boutin, Robert D. , Zandee van Rilland, Eddy D , Brown, Ian P , Chang, Eric Y , Chow, Lawrence C , Gatz, J David , Garner, Hillary W , Gorbachova, Tetyana , Guermazi, Ali , Halle, Tyler R , Hanna, Tarek N , Kornblith, Aaron E , Lopez-Ben, Robert R , Mann, Edana D , Moore, Christopher L. , Obey, Mitchel R , Patel, Zara , Raja, Ali S , Rendon, Juan M , Sabbatini, Amber K , Tannoury, Chadi , Yu, Joseph S , Boutin, Robert D , Link, Thomas M , Desai, Shaun C. , Fritz, Jan , Garner, Hillary W. , Gray, Mingyang Liu , Hall, M. Kennedy , Osgood, Greg Michael

Mayo Clinic

Radiology | May 19, 2026 | Volume: 319 | Issue: 2 | Pages: No page available

10.1148/radiol.252309 | PMID 42153836 Get It

Expert consensus recommendations from 21 academic centers were established for appropriate radiography utilization at 12 potentially low-yield anatomic sites through a multidisciplinary process endorsed by six major American medical societies.
Global Longitudinal Assessment of MASLD Using Magnetic Resonance Elastography ( GOLDMINE ): A Multi‐Center, International Prospective Cohort Study of Imag
Sharpton, Suzanne R. , Diaz, Luis Antonio, Pepin, Kay , Amangurbanova, Maral , Madamba, Egbert , Bettencourt, Ricki , Singh, Seema, Dalupang, Mary, Tesfai, Kaleb , Middleton, Michael S. , Behling, C, Nakajima, Atsushi , Imajo, Kento , Ogawa, Yuji, Halegoua‐DeMarzio, Dina, Huang, Daniel Q., Balakrishnan, Maya, Gray, Meagan , Rodriguez, Manuel, DeLeon, Andre, Puskoor, Rohit, Behari, Jaideep , Hansen, Lars, Miller, Cynthia, Medici, Valentina , Boursier, Jerome, Richards, Lisa, Díaz, Luis Antonio , Sharpton, Suzanne , Díaz, Luis A , Nakajima, Atsushi , Imajo, Kento , Huang, Daniel Q , Vuppalanchi, Raj , Medici, Valentina , Tincopa, Monica , Ehman, Richard , Singh, Seema, Valasek, Mark A. , Dunn, Winston , Caussy, Cyrielle , Mohanty, Arpan , Huang, Daniel Q. , Fuchs, Michael A. , Hameed, Bilal , Stine, Jonathan G. , Balakrishnan, Maya , Vuppalanchi, Raj , Sarkar, Souvik , Boursier, Jerome, Tincopa, Monica A. , Ajmera, Veeral , Sirlin, Claude B. , Ehman, Richard L. , Loomba, Rohit

Mayo Clinic

Alimentary Pharmacology & Therapeutics | April 22, 2026 | Volume: 64 | Issue: 3 | Pages: 334-344

10.1111/apt.70696 | PMID 42017265 Get It

ABSTRACT Background Metabolic dysfunction‐associated steatotic liver disease (MASLD) exhibits marked heterogeneity in fibrosis progression and liver‐related outcomes. Liver biopsy is not feasible for longitudinal risk stratification at scale, creating a need for validated non‐invasive biomarkers, particularly imaging biomarkers, that can predict clinically meaningful disease progression and liver‐related outcomes. Aims To describe the design and rationale of the GOLDMINE study, established to determine whether non‐invasive imaging biomarkers predict MASLD progression and liver‐related clinical outcomes. Methods GOLDMINE is an investigator‐initiated, multi‐centre, international longitudinal cohort enrolling up to 1000 adults with either biopsy‐proven MASLD or MASLD cirrhosis across the full fibrosis spectrum. Participants are recruited from 15 sites in the US and 4 international sites (Japan, Singapore and France). At baseline, participants undergo clinical phenotyping, vibration‐controlled transient elastography, and advanced magnetic resonance imaging (MRI), including proton‐density‐fat‐fraction and magnetic resonance elastography (MRE). MRI (and biospecimen banking) is repeated at 2‐year intervals (years 2 and 4), with annual follow‐up visits for up to 10 years. Baseline liver histology is centrally processed, digitized and reviewed by a single expert hepatopathologist; all MRI/MREs are centrally interpreted. Results The prespecified clinical outcomes include progression to cirrhosis, clinically significant portal hypertension, major adverse liver‐related outcomes (ascites, hepatic encephalopathy, portal hypertensive bleeding, liver transplantation/qualification), hepatocellular carcinoma, major adverse cardiovascular events, and all‐cause mortality, with independent central adjudication of all events. Conclusions GOLDMINE establishes a rigorously phenotyped MASLD cohort integrating centralized histology, advanced MRI‐based biomarkers, longitudinal biobanking, and adjudicated outcomes, providing a platform to validate imaging and blood‐based prognostic biomarkers in MASLD.
Predicted versus observed outcomes in the ALT-FLOW early feasibility study
Fioretti, Francesco , Gray, William A, Hibbert, B, Lindenfeld, JoAnn, Tedford, Ryan J, Zahr, Firas, Butler, Javed , Butler, Javed , Gray, William A. , Hibbert, Benjamin , Lindenfeld, JoAnn , Tedford, Ryan J. , Zahr, Firas

Mayo Clinic

ESC Heart Failure | April 3, 2026 | Volume: 13 | Issue: 3 | Pages: No page available

10.1093/eschf/xvag101 | PMID 42257333 Get It

Abstract Background and Aims Whether hemodynamic and symptomatic benefits of the APTURE left atrial-to-coronary sinus shunt translate into clinical outcome benefit in heart failure with left ventricular ejection fraction &gt;40% remains unknown. Methods In this post hoc analysis of ALT-FLOW EFS patients undergoing APTURE implantation, Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) score-predicted 1-year all-cause mortality was compared with observed mortality by Kaplan-Meier analysis of adjudicated events. Heart failure hospitalization (HFH) rates were compared for the 12 months before vs after implantation. Additional analyses included stratification by baseline sodium-glucose cotransporter 2 inhibitor (SGLT2i) use and N-terminal pro-B-type natriuretic peptide (NT-proBNP), recurrent HFH cumulative hazard estimation (Nelson-Aalen), and H2FPEF score calculation. Results Among 95 patients (mean age 70.9 ± 8.5 years; 50% women; 93% New York Heart Association Class III; 85.9% with H2FPEF score &gt;3), MAGGIC-predicted 1-year mortality was 13.0%. Observed 1-year survival was significantly higher than predicted (94.7% vs 87.0%; P=0.04), consistent across SGLT2i subgroups (log-rank P=0.59). The proportion of patients with HFH declined from 37.9% pre implantation to 9.6% post implantation (P&lt;0.0001), with event rates falling from 0.61 to 0.21 per patient-year (P&lt;0.001) and a 1-year cumulative hazard of recurrent HFH of 0.19 (95% confidence interval, 0.12-0.31). HFHs were evenly distributed across NT-proBNP strata. Conclusions In ALT-FLOW EFS, observed 1-year mortality was lower than MAGGIC-predicted mortality, and post implantation HFH rates were lower than pre implantation rates. These hypothesis-generating findings will require confirmation in the randomized, sham-controlled ALT-FLOW II trial.